Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
MYRIAD GENETICS INC (MYGN) reported a Form 4 for Chief Legal Officer Jennifer Lynne Fox showing that on September 3, 2026, 4,398 shares of Common Stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These withheld shares were treated as a disposition for reporting purposes at $3.23 per share, based on the closing price on that date, and were not an open-market sale. After this tax-withholding event, Fox directly held 305,964 shares of MYGN Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC (MYGN) is reported to have 9,900,937 shares of its common stock beneficially owned by BlackRock Portfolio Management LLC and certain related business units of BlackRock, Inc., representing 10.4% of the class as of the filing.
BlackRock Portfolio Management LLC reports sole power to vote 8,751,792 shares and sole power to dispose of 9,900,937 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Myriad Genetics’ outstanding common shares.
MYRIAD GENETICS INC executive Benjamin Richard Wheeler, Chief Financial Officer, reported a Form 4 transaction involving company common stock. On August 16, 2026, 8,761 shares were withheld by the issuer to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. After this tax-withholding disposition, Wheeler’s directly held common stock position is 289,748 shares.
Myriad Genetics, Inc. received an updated ownership report from Glenview Capital Management, LLC and Larry Robbins. As of June 30, 2026, the reporting persons state they may be deemed the beneficial owners of 0 shares of Myriad Genetics common stock, representing 0% of the outstanding shares. The filing confirms they hold no sole or shared voting or dispositive power over any Myriad Genetics shares, indicating they no longer report a significant ownership position in the company.
Myriad Genetics, Inc. has a new large shareholder disclosure from Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder. The reporting group states beneficial ownership of 5,735,000 shares of Myriad Genetics common stock, representing 6.1% of the outstanding shares.
The stake is held through a Vestal Point fund and a managed account, for which Vestal Point Capital, LP acts as investment adviser. The reporting persons report shared voting and dispositive power over all 5,735,000 shares and no sole voting or dispositive power. The ownership percentage is based on 94,448,210 shares of common stock outstanding as of May 1, 2026.
State Street Corporation reported beneficial ownership of common stock of Myriad Genetics, Inc.. State Street disclosed beneficial ownership of 4,985,060 shares of common stock, representing 5.3% of the class.
All voting and dispositive authority is held on a shared basis through asset management subsidiaries, with 4,866,068 shares having shared voting power and 4,985,060 shares having shared dispositive power, and no sole voting or dispositive power reported.
Myriad Genetics, Inc. reported second quarter 2026 revenue of $190.7 million, an 11% decline year-over-year, as total test volumes were essentially flat at 379,000 but average revenue per test fell 9%, including an $11.0 million revenue reduction from updated collection estimates. Gross margin was 66.6%, down 460 basis points from the prior-year quarter, and operating loss was $38.9 million. Net loss was $43.2 million, or $0.46 per share. Adjusted EBITDA was $(16.9) million.
Cancer Care Continuum revenue was $114.1 million with 6% volume growth, Prenatal Health revenue was $39.8 million, down 16%, and Mental Health revenue was $36.8 million, down 3%. The company highlighted launches and expansions including Prolaris + AI and broader Precise MRD usage, and submitted Precise MRD breast for MolDX Medicare coverage. Cash and cash equivalents were $115.2 million with long-term debt of $120.7 million. For full-year 2026, Myriad now guides revenue to $770–$790 million and Adjusted Gross Margin to 66–67%, and has suspended prior Adjusted EBITDA guidance while implementing its Ascend efficiency initiative and broader strategic review.
Myriad Genetics director Daniel Skovronsky filed a Form 4 reporting his direct holdings in the company. The filing lists ownership of 195,507 shares of Common Stock after the reported entry. The record is characterized as a holdings entry, not as a new purchase or sale.
Myriad Genetics, Inc. reported that Board member Daniel M. Skovronsky, M.D., Ph.D., resigned as a director effective June 17, 2026. The company states his resignation was not due to any disagreement with Myriad Genetics or any matter related to its operations, policies, or practices.